Ventilation defect percent in helium-3 magnetic resonance imaging as a biomarker of severe outcomes in asthma

David G. Mummy, Stanley J. Kruger, Wei Zha, Ronald L. Sorkness, Nizar N. Jarjour, Mark L. Schiebler, Loren C. Denlinger, Michael D. Evans, Sean B. Fain

Research output: Contribution to journalArticlepeer-review

17 Scopus citations
Original languageEnglish (US)
Pages (from-to)1140-1141.e4
JournalJournal of Allergy and Clinical Immunology
Volume141
Issue number3
DOIs
StatePublished - Mar 2018
Externally publishedYes

Bibliographical note

Funding Information:
This work was supported by the National Institutes of Health (grant nos. R01 HL080412 , R01 HL069116 , U10 HL109168 , and UL1TR000427 ), GE Healthcare, and the Wisconsin Alumni Research Foundation Technology Training Research Assistantship.

Funding Information:
Disclosure of potential conflict of interest: D. G. Mummy's institution received grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) (grant no. U01 HL109168), GE Healthcare, and Wisconsin Alumni Research Foundation for this work. R. L. Sorkness' institution received a grant from the NIH-NHLBI for this work and other works. N. N. Jarjour's institution received a grant from the NIH (grant no. U10HL109168 to N.N.J.) for this work; he personally received consultancy fees from Teva Pharmaceuticals, Astrazeneca, and Daiichi Sankyo; the institution received grants P01HL088584 (N.N.J.), 1R01HL109031-01 (Fiore), U10 HL098090 (Lemanske, R.L.S.), UL1TR000427 (Drezner), R01HL123284 (Busse), and RFA-HL-17-009 (L.C.D/N.N.J.) for other works. M. L. Schiebler's institution received a grant, support for travel, fees for review activities, payments for reviewing/writing this manuscript, and provision of writing assistance from the NHLBI/NIH for this work; the institution received grants, patents, royalties, payment for development of educational presentations, stock/stock options, and travel accommodations from the NHLBI/NIH for other works. L. C. Denlinger's institution received a grant from the NIH for this work; he personally received consultancy fees from GSK and Novartis; his institution received grants from the NIH for other works. M. D. Evans' institution received a grant from the NIH for this work. S. B. Fain's institution received a grant from the NIH/NHLBI (grant no. U01 HL109168) and from GE Healthcare for this work; he personally received consultancy fees from GE Healthcare. The rest of the authors declare that they have no relevant conflicts of interest. Letter to the Editor

Cite this